Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03329391
Other study ID # 201612198RINB
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date January 9, 2018
Est. completion date October 30, 2020

Study information

Verified date June 2020
Source National Taiwan University Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Pharmacotherapy and psychotherapy, effective management strategies for treatment-resistant depression are limited and yet to be developed. However, nursing interventions focusing on adherence enhancement, symptom reduction, and stress management may be strategic for a better disease management. This study aimed to define the rarely-studied concept of TRD under the cultural context of Taiwan and to identify new feasible and complementary treatment model from nursing perspectives. The project had established important basis on the descriptions of psychosocial features and need assessment of people with TRD over psychiatrist's validation. The findings also built up a cultural-specific non-pharmacological intervention module for effective TRD management in Taiwan. The nursing model of TRD management will further promote the development of integrative depression care in the future and complement current modalities, while providing important evidence-based information for future research and services.


Description:

The three-year pioneering project began with observing the psychosocial characteristics and demographic profile of a group of TRD cohort, followed by validating the cultural meanings and recovery constructs of TRD through professional and lay focus groups in the first year. In the second to third year, we examined the effectiveness of a 8-week, nurse-led psychosocial intervention with group approach in a randomized control trial (RCT) compared to the controls receiving usual care with three follow-ups. Detailed psychiatric assessment and study interviews have been performed at baseline, 3, 6, and 9 months after the intervention by a senior psychiatrist and a research assistant using standardized operation forms.Structured measurements have been utilized to collect primary outcome variables of psychological distress, suicide risk and resilience as well as secondary outcome measures of quality of life, community reintegration level, perceived satisfaction, and main clinical variables (e.g., treatment adherence, service use such as ER/OPD attendance or hospitalization days). The control group receives usual care of pharmacological therapy provided by the psychiatrists in the Psychiatric Department of the study hospital in northern Taiwan.


Recruitment information / eligibility

Status Completed
Enrollment 46
Est. completion date October 30, 2020
Est. primary completion date September 22, 2020
Accepts healthy volunteers No
Gender All
Age group 20 Years to 85 Years
Eligibility Inclusion Criteria: 1. Aged 20-85 ; 2. To be diagnosed with Major Depressive disorder or Bipolar II disorder; 3. Failed to respond to at least three weeks of two antidepressant trials ; 4. Able to communicate with Mandarin or Taiwanese ; 5. No severe or foreseeing cognitive impairment during study period judged by the co-PI; 6. Willing to sign the informed consent. Exclusion Criteria: 1. Unable to cooperate due to psychiatric symptom disturbance ; 2. Unwilling to provide most information in the questionnaire ; 3. Severely suicidal during study period

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Nurse-led cognitive-behavioral-based group intervention
The intervention focused on the following topics of symptom awareness(i.e. provision of literacy in depression and stress), stress management, lifestyle restructuring and emotional self-care. These topics have been integrated as four major domains for discussions in the eight-weekly sessions. Each session starts with open discussion for participants' daily concerns to activate group dynamics, followed by second part of domain-oriented discussions, and then the third part of session review and homework reminder.

Locations

Country Name City State
Taiwan Chia-Yi Wu Taipei

Sponsors (2)

Lead Sponsor Collaborator
National Taiwan University Hospital Shin Kong Wu Ho-Su Memorial Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change of score of the Brief Symptom Rating Scale(BSRS-5) for psychological distress level The full scale contains five items of psychopathology: (1) anxiety; (2) depression; (3) hostility; (4) interpersonal sensitivity: inferiority; and (5) insomnia. An extra question "Do you have any suicide ideation?" is added at the end of the scale. It is a 5-item Likert scale (scores of 0 to 4) for assessment of psychological distress level by self-report of by interview. The rating of symptoms is based on a 5-point scale: 0, not at all; 1, a little bit; 2, moderately; 3, quite a bit; 4, extremely. Total score will be calculated based on the 5 questions with a maximum score of 20, where a higher score indicates higher level of psychological distress and poorer mental health status in the past week. Baseline assessment and follow up sessions on 3,6, and 9 months
Primary The change of score in 9-item Concise Mental Health Checklist (CMHC-9) for suicide risk assessment The CMHC-9 is consisted of 9 items assessing psychopathgology (5 items) and suicide risk (4 items). The five item evaluated recent mental distress, lending the measurement from the BSRS-5, i.e., insomnia, anxiety, hostility, depression, and inferiority. The four items reflecting several key suicide risk factors, including lifetime suicide attempt, future suicide intent, alcohol or drug abuse history, and lack of social support. Each item was rated by 0/1, indicating the existence of each symptom, with a total score ranging from 0 to 9. The higher the score, the higher the risk of suicide. The cutoff at 4 points indicates a higher overall suicide risk among clinical or community population. Baseline assessment and follow-up session on the 9th month
Primary Change of score in Brief Resilience Coping Scale (BRCS) for tendencies to cope with stress It is a 4-item measurement tool designed to assess the ability of an individual to cope with stress in a resilient fashion. The response consists of five options at which 1 means the statement "does not describe you at all" and 5 means "it describes you very well". The score is then added up.Among general public, the score of 4-13 indicates low resilient copers; 14-16 indicates medium resilient copers; and 17-20 indicates high resilient copers. However, the scores will undergo validation among a cohort of TRD patients in this study. Baseline assessment and follow up sessions on 3,6, and 9 months
Secondary Community Integration Questionnaire-Revised (CIQ-R) for the participants' level of community integration CIQ-R consists of four domains: home integration, social integration, productivity, andelectronic social networking score. The scale contains 18 items. The home integration subscale is made up of 5 items at which each item is scored from 0-2, where 2 indicates highest degree of integration. The Social Integration subscale consists 6 items with the same scoring method mentioned above. The productivity subscale consists of 4 questions with a total points of 7. The electronic social networking subscale consists of 3 questions with a total points of 6. Scores of these subscales are then added up as an overall CIQ score. Maximum score is 35, which represents maximum community reintegration. Follow up sessions on 3, 6, and 9 months
Secondary EQ-5D questionnaire for quality of life The EQ-5D is a self-completed questionnaire which contains five dimensions: mobility, self-care, usual activities, pain-discomfort, and anxiety-depression. The level of function in each dimension is classified into three degrees of disability, which is level 1(no disability), level 2(moderate disability), and level 3(severe disability). These responses will then generate a 5-digit descriptor ranging from 1-1-1-1-1 indicating perfect health to 3-3-3-3-3 indicating worth possible state. It is accompanied by a visual analogue scale (EQ-VAS) to assess perceived health conditions, which ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). Follow up sessions on 3, 6, and 9 months
See also
  Status Clinical Trial Phase
Completed NCT02497287 - A Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression Phase 3
Recruiting NCT03653858 - Efficacy Study of Deep Brain Stimulation in Patients With Treatment Resistant Major Depression N/A
Recruiting NCT02462551 - Focal Electrically Administered Seizure Therapy for the Treatment of Depression N/A
Recruiting NCT01868802 - Ketamine for Treatment-resistant Depression: A Multicentric Clinical Trial in Mexican Population Phase 2
Recruiting NCT05377177 - Cortical Inhibition as a Biomarker of Response in a Comparison of Bilateral Versus Unilateral Accelerated Theta Burst Stimulation for Suicidal Ideation in Treatment-Resistant Depression -COMBAT-SI N/A
Completed NCT05095792 - Effect of Ketamine on Neurological Activity as Measured by Electroencephalogram (EEG)
Recruiting NCT06372834 - Adjuvant Accelerated piTBS for Reducing Suicidal Ideation in TRD Patients: A Randomized, Sham-controlled Trial N/A
Active, not recruiting NCT03701724 - Cost-utility Analysis of Maintenance rTMS for Treatment-resistant Depression N/A
Recruiting NCT05800860 - A Trial of GH001 in Patients With Treatment-resistant Depression Phase 2
Not yet recruiting NCT06404320 - Physical Activity Program for TRD N/A
Completed NCT01945047 - Action of Ketamine in Treatment-Resistant Depression Phase 2/Phase 3
Recruiting NCT05045378 - Low-dose Ketamine Infusion Among Adolescents With Treatment-resistant Depression Phase 4
Completed NCT05454410 - Study of Efficacy, Safety, Tolerability and Pharmacokinetics of MIJ821 in Participants With Treatment- Resistant Depression (TRD) Phase 2
Recruiting NCT05422417 - Dorsomedial Prefrontal Neuromodulation in Treatment-resistant Depression N/A
Recruiting NCT05842291 - pBFS Guided High-dose rTMS Therapy for Treatment-Resistant Depression N/A
Recruiting NCT04821271 - Antidepressant Effects of TS-161 in Treatment-Resistant Depression Phase 2
Active, not recruiting NCT04670081 - Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression Phase 2
Terminated NCT01598324 - Functional and Neurochemical Correlates of Treatment Response in Major Depressive Disorder N/A
Recruiting NCT05710237 - Does Psilocybin Require Psychedelic Effects to Treat Depression? Phase 2
Not yet recruiting NCT05661383 - Olfactory and Brain Stimulations in Treatment-resistant Depression N/A

External Links